Praxis precision medicines to participate in three upcoming november investor conferences

Boston, nov. 06, 2024 (globe newswire) -- praxis precision medicines, inc. (nasdaq: prax), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (cns) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will be participating in three upcoming investor conferences in november 2024.
PRAX Ratings Summary
PRAX Quant Ranking